Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

导出 OA

翻译打印收藏纠错

作者： D J,DeAngelo ^[1] ; K E,Stevenson ^[2] ; S E,Dahlberg ^[2] ; L B,Silverman ^[3] ; S,Couban ^[4] ; J G,Supko ^[5] ; P C,Amrein ^[5] ; K K,Ballen ^[5] ; M D,Seftel ^[6] ; A R,Turner ^[7] ; B,Leber ^[8] ; K,Howson-Jan ^[9] ; K,Kelly ^[10] ; S,Cohen ^[11] ; J H,Matthews ^[12] ; L,Savoie ^[13] ; M,Wadleigh ^[1] ; L A,Sirulnik ^[1] ; I,Galinsky ^[1] ; D S,Neuberg ^[2] ; S E,Sallan ^[3] ; R M,Stone ^[1]

作者单位： Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ^[1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. ^[2] Department of Pediatric Oncology, Dana-Farber Cancer Institute/Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA. ^[3] 1] National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada [2] Dalhousie University, Halifax, Nova Scotia, Canada. ^[4] Massachusetts General Hospital, Boston, MA, USA. ^[5] Cancer Care Manitoba, Winnipeg, Manitoba, Canada. ^[6] Cross Cancer Institute, Edmonton, Alberta, Canada. ^[7] Hamilton Health Sciences Center, Hamilton, Ontario, Canada. ^[8] London Health Services, London, Ontario, Canada. ^[9] Columbia University Medical Center, New York, NY, USA. ^[10] Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada. ^[11] Queen's University, Kingston, Ontario, Canada. ^[12] Tom Baker Cancer Center, Calgary, Alberta, Canada. ^[13]